Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reducing The Pain Of Skin R&D: Almirall And Leo Collaborate

Executive Summary

Two European companies with portfolios in skin conditions have taken their first collaborative steps, researching non-painful skin sampling.

You may also be interested in...



Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain

Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.

Almirall Taps Evotec For Novel Dermatology Mechanism

The Spanish derma specialist has agreed a research collaboration that could yield novel therapies for diseases such as psoriasis and atopic dermatitis.

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC098824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel